country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-164702

Copy Link Print Information

BL-B01D1

Name: BL-B01D1
Brand: MedChemExpress
SKU: HY-164702
Price: 1450.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: Izalontamab Brengitecan)

Kundenbewertung

Based on 1 Customer Validation

BL-B01D1 (Izalontamab Brengitecan) is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab (HY-P99676) to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide (HY-153891) via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.53%
Molecular Weight:205830.00

Speicherung:

-80°C, protect from light

BL-B01D1 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]

Topoisomerase I

EGFR

HER3

Alle EGFR Isoform-spezifische Produkte anzeigen :

Alle Topoisomerase Isoform-spezifische Produkte anzeigen :

In Vivo

BL-B01D1 (Izalontamab Brengitecan) exhibits superior in vivo antitumor activity compared to single-target EGFR or HER3 antibody-drug conjugates in cancer-patient-derived tumor xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Appearance Liquid
Molecular Weight 205830.00
Color Colorless to light yellow
SMILES

[BL-B01D1]
Synonyms

Izalontamab Brengitecan
Versand

Shipping with dry ice.
Speicherung

-80°C, protect from light

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wan W, et al. Abstract 2642: BL‑B01D1, a novel EGFR×HER3‑targeting ADC, demonstrates robust anti‑tumor efficacy in preclinical evaluation. Cancer Research. 2023 Apr 4;83(7_Supplement):2642.

[2]. Liu C, et al. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025 Oct;31(10):3485-3491.

[3]. Ma Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024 Jul;25(7):901-911. [Content Brief]

[4]. Bian X, et al. Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Nov 10;43(32):3505-3515.

[5]. Zhang L, et al. BL‑B01D1, a first‑in‑class EGFR×HER3 bispecific antibody‑drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first‑in‑human phase 1 study. Journal of Clinical Oncology. 2023 Jun;41(16_suppl):3001.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BL-B01D1

Becotatug vedotin

Izalontamab

Patritumab deruxtecan

Datopotamab deruxtecan (solution)

Amivantamab

Telisotuzumab Adizutecan

Ifinatamab deruxtecan

Trastuzumab deruxtecan

Cetuximab

Deruxtecan

Deruxtecan 2-hydroxypropanamide

Enfortumab vedotin-ejfv

Alle EGFR Isoform-spezifische Produkte anzeigen

Alle Topoisomerase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Bioz

BL-B01D1

Becotatug vedotin

Izalontamab

Patritumab deruxtecan

Datopotamab deruxtecan (solution)

Amivantamab

Telisotuzumab Adizutecan

Ifinatamab deruxtecan

Trastuzumab deruxtecan

Cetuximab

Deruxtecan

Deruxtecan 2-hydroxypropanamide

Enfortumab vedotin-ejfv

Alle EGFR Isoform-spezifische Produkte anzeigen

Alle Topoisomerase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

BL-B01D1 Related Classifications

HY-164702 Related Classifications

Bioz